To identify the correlation between existing T cell phenotypes in the peripheral blood of patients with NSCLC and their clinical response during cancer immunotherapy with PD-1/PD-L1 blockade, we conducted flow cytometry analyses of CD4+ and CD8+ T cells derived from the PBMCs of patients with NSCLC at baseline. The gene discussed is CD4; the disease is cancer.